FDA makes 2 drug and vaccine chiefs permanent, with UAE pharmacy implications

The US Food and Drug Administration has made Dr. Michael Davis its permanent drug chief and Karim Mikhail its permanent vaccines chief, a personnel decision that matters in the UAE because many imported medicines and vaccines arrive with US regulatory data behind them.

For Dubai clinics and pharmacies, the immediate issue is operational. The Dubai Health Authority (DHA) licenses healthcare facilities in Dubai, while federal product registration and import control sit with the UAE medicines regulator. In Abu Dhabi, the Department of Health Abu Dhabi (DOH Abu Dhabi) oversees providers, claims rules and payer data infrastructure. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, the Ministry of Health and Prevention (MOHAP) remains the relevant health system regulator for facilities and professionals.

What changed at FDA

The Associated Press, carried by WTVB, reported on 8 September 2026 that the Trump administration filled four senior FDA posts. Davis will lead the Center for Drug Evaluation and Research, which reviews prescription and over-the-counter drugs. Mikhail will lead the FDA vaccines center on a permanent basis. The same announcement named Bret Koplow to tobacco products and Jared Seehafer to a new artificial intelligence and technology oversight role.

The FDA appointments follow several departures in 2026. AP reported that former vaccine chief Dr. Vinay Prasad resigned in March 2026 after disputes over vaccines, gene therapies and biotech medicines. Former commissioner Dr. Marty Makary resigned in May 2026. For drug manufacturers, the appointment of permanent center heads reduces one source of uncertainty, although policy direction can still change through guidance, advisory committee voting and product-specific reviews.

Davis is relevant to UAE mental health providers because AP said he will oversee reviews of psychedelic medicines studied for psychiatric conditions, including psilocybin, MDMA and LSD. These products would still need UAE approval before routine use. A US approval would give medical directors evidence to monitor, not a license to prescribe in Dubai, Abu Dhabi or the northern emirates.

Why UAE operators should watch it

UAE pharmacy teams should treat FDA decisions as an early signal for formulary work, payer discussions and patient questions. A US approval can affect expectations among expatriate patients within days, especially for oncology, rare disease, vaccines and psychiatry. Local access still depends on UAE registration, import status, payer coding and facility policy.

• COOs should ask pharmacy leads to track FDA approvals monthly and separate US-approved products from UAE-available products in patient-facing scripts.
• CFOs should check whether high-cost drugs need prior authorization under payer rules before stocking them.
• Medical directors should review vaccine label changes before changing clinic protocols.
• CIOs should keep drug master files, e-prescribing systems and claims dictionaries current when products enter local formularies.

For price work, UAE operators should avoid using US list prices as local budget inputs. Dubai teams should check DHA systems and payer contract schedules. Abu Dhabi teams should check DOH Abu Dhabi's Shafafiya dictionary, which lists codes, drug files, benefit packages and pharmacy claim resources. Payers such as Daman, Thiqa and Sukoon may apply different rules by network, plan type and prior authorization status. The number to use is the current contracted reimbursable price, not the US launch price.

Impact on vaccines and patients

Mikhail's FDA role matters because vaccine policy changes move quickly through media, travel clinics and paediatric practices. AP reported that Prasad and Makary had supported stricter requirements for updated COVID-19 shots, including new studies before approval for healthy adults and children. UAE providers should wait for DHA, DOH Abu Dhabi or MOHAP circulars before changing eligibility, consent language or appointment protocols.

The patient impact is practical. Clinics will face questions about whether a US vaccine recommendation applies in Dubai or Abu Dhabi. The answer should cite the current UAE regulator, the product label and the payer policy. Where eligibility is unclear, providers should document the clinical reason, the regulator status and the payer response before administration.

The commercial impact is also uneven. A large hospital pharmacy can absorb a temporary stock position for a new biologic or vaccine. A small clinic pharmacy may have cash tied up in cold-chain inventory that cannot be reimbursed. That is a P&L risk if the drug is FDA-approved but absent from a UAE payer formulary.

What's next: UAE operators should build a 30-day watchlist for FDA drug and vaccine decisions, then map each item against UAE registration, DHA or DOH Abu Dhabi coding, payer prior authorization and cold-chain requirements. Licensed pharmacy providers can be checked through the UAE Open Healthcare Directory before referral, stocking or network discussions.